Duyuru • May 07
Carlsmed, Inc. Raises Earnings Guidance for the Full Year 2026 Carlsmed, Inc. raised earnings guidance for the full year 2026. For the year, company expected revenue to be in the range of $72 to $77 million, representing growth of 48% at the midpoint of the range over 2025. This compares to prior guidance of $70 to $75 million. Reported Earnings • May 06
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: US$0.32 loss per share. Revenue: US$16.1m (up 58% from 1Q 2025). Net loss: US$8.70m (loss widened 38% from 1Q 2025). Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) also surpassed analyst estimates by 18%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Duyuru • Apr 23
Carlsmed, Inc., Annual General Meeting, Jun 03, 2026 Carlsmed, Inc., Annual General Meeting, Jun 03, 2026. Location: at the offices of morrison & foerster llp, located at 12531 high bluff drive, suite 200, ca 92130, san diego, United States Duyuru • Apr 14
Carlsmed, Inc. to Report Q1, 2026 Results on May 05, 2026 Carlsmed, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 05, 2026 Recent Insider Transactions Derivative • Mar 03
Co-Founder notifies of intention to sell stock Michael Cordonnier intends to sell 198k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of March. If the sale is conducted around the recent share price of US$13.29, it would amount to US$2.6m. For the year to December 2024, Michael's total compensation was 70% salary and 30% non-salary. Since June 2025, Michael's direct individual holding has increased from 221.46k shares to 1.24m. Company insiders have collectively bought US$8.1m more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Feb 26
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: US$2.13 loss per share. Revenue: US$50.5m (up 86% from FY 2024). Net loss: US$30.2m (loss widened 22% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 12%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Duyuru • Feb 26
Carlsmed, Inc. Provides Revenue Guidance for the Year 2026 Carlsmed, Inc. provided Revenue guidance for the year 2026. Revenue for 2026 is expected to be in the range of $70 to $75 million, representing growth at the midpoint of the range of 44% over 2025. Duyuru • Feb 19
Carlsmed, Inc. Announces First Corra™ Personalized Cervical Plating Procedure Carlsmed, Inc. announced the first personalized cervical plating procedure using the corra Cervical Plating System, the latest addition to its portfolio of personalized spine surgery solutions. The procedure, which was performed by Dr. Aaron Clark at the University of California San Francisco (UCSF), represents an important milestone as the Company prepares for the planned commercial launch of the corra™? system later this year. The corra™? Cervical Plating System is designed to stabilize the cervical spine during fusion procedures using patient-specific plates tailored to each individual's anatomy and surgical plan. Utilizing Carlsmed's digital surgery ecosystem, key anatomical aspects including screw positioning and plate curvature are tailored pre-operatively to each vertebral level, helping support consistent fixation and precise alignment for Anterior Cervical Discectomy and Fusion (ACDF) procedures. When used in conjunction with the aprevo®? cervical planning and interbody fusion devices, the corra™? Personalized Plating System can provide anatomical fit and fixation for patients. Data from the clinical evaluation will inform continued product refinement as Carlsmed prepares for broader market introduction. The Company expects to conduct additional evaluations in the coming months and anticipates commercial launch later this year. Duyuru • Feb 12
Carlsmed, Inc. to Report Q4, 2025 Results on Feb 25, 2026 Carlsmed, Inc. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026 Duyuru • Feb 11
Carlsmed, Inc. Announces First Aprevo Bi-Lateral Posterior Lumbar Interbody Fusion Procedure Carlsmed, Inc. announced the successful completion of the first posterior lumbar spine surgery using the Company's aprevo Lumbar Bi-lateral Posterior System. The procedure was performed by Orthopedic Spine Surgeon CJ Kleck, M.D. at the University of Colorado Hospital in Denver, Colorado. Carlsmed's Bi-lateral Posterior Fusion System integrates seamlessly with the Company's broader aprevo platform technology, which combines proprietary AI-enabled software and clinical intelligence to deliver personalized surgical strategies and preoperative planning across a range of spinal pathologies. The Company expects to commercially launch the system later this year. Duyuru • Jan 07
Carlsmed Aprevo Lumbar 2-Year Data Published in Global Spine Journal Carlsmed, Inc. announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating that 3D preoperative planning combined with patient-specific, anatomically designed interbody implants significantly reduces mechanical complication-related reoperations in complex adult spinal deformity (ASD) surgery. The study compared 2-year revision rates among ASD patients receiving Carlsmed's aprevo®? personalized interbody implants with revision data from a similar patient cohort receiving conventional stock implants. The comparator cohort was drawn from the multicenter dataset of the International Spine Study Group, which is comprised of senior spine surgeons dedicated to advancing the treatment of adult spinal deformity. Patients treated with aprevo®? experienced significantly fewer revisions due to mechanical complications, showing a revision rate of 4.3% (n=115) compared with 16.6% (n=997) using stock devices (pp). Board Change • Dec 31
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Kevin O’Boyle was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Dec 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 5.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$33m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Reported Earnings • Nov 07
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: US$0.40 loss per share. Net loss: US$8.53m (flat on 3Q 2024). Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 5.3%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Duyuru • Nov 07
Carlsmed, Inc. Raises Earnings Guidance for the Full Year 2025 Carlsmed, Inc. raised earnings guidance for the full year 2025. For the year, the company's revenue for the full year 2025 is expected to be in the range of $49.0 million to $50.0 million, representing growth of 80% to 84% over 2024. This compares to prior guidance of $45.5 million to $47.5 million. Duyuru • Oct 24
Carlsmed, Inc. to Report Q3, 2025 Results on Nov 06, 2025 Carlsmed, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025 Duyuru • Sep 30
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary, Effective September 29, 2025 Carlsmed, Inc. announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective September 29, 2025. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance. Ms. Kamocsay brings more than two decades of corporate legal experience as in-house counsel across life science and technology sectors at Akoya Biosicences, Rubius Therapeutics, Inc. and Progress Software Corporation. Prior to Akoya, Ms. Kamocsay served as General Counsel and Corporate Secretary of Rubius Therapeutics, Inc., where she was responsible for overseeing and managing all of the company’s legal affairs. Before Rubius, she served as Associate General Counsel and Assistant Secretary at Progress Software Corporation, where she managed the company’s corporate, securities law, and M&A initiatives. Ms. Kamocsay began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she provided counsel to public and private company clients in the biotechnology and pharmaceutical industries on M&A, securities law, and corporate governance matters. Ms. Kamocsay holds a B.A. in History from the University of California, Los Angeles and a J.D. from Northeastern University School of Law. Reported Earnings • Aug 31
Second quarter 2025 earnings: EPS misses analyst expectations Second quarter 2025 results: US$1.47 loss per share. Net loss: US$6.77m (flat on 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Duyuru • Aug 29
Carlsmed, Inc. Provides Earnings Guidance for the Full Year 2025 Carlsmed, Inc. provided earnings guidance for the full year 2025. For the year, the company expects revenue to be in the range of $45.5 million to $47.5 million, representing growth of 67% to 75% over 2024. New Risk • Aug 18
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 8.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 8.1% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$38m net loss in 3 years). Duyuru • Aug 14
Carlsmed, Inc. to Report Q2, 2025 Results on Aug 28, 2025 Carlsmed, Inc. announced that they will report Q2, 2025 results After-Market on Aug 28, 2025 Duyuru • Jul 29
Carlsmed's Aprevo Powers First Personalized Cervical Spine Surgery Carlsmed, Inc. announced the successful completion of the first aprevo cervical procedure on July 14, 2025 by Joseph Osorio, MD, PhD, Chief of Spine Surgery in the Department of Neurological Surgery at UC San Diego (UCSD) Health in San Diego, CA. The aprevo devices are designed to match the unique anatomical and alignment needs of each patient through Carlsmed's proprietary AI-powered surgical planning platform and digital production system. Recent Insider Transactions • Jul 27
Independent Director recently bought US$7.0m worth of stock On the 24th of July, Jonathan Root bought around 467k shares on-market at roughly US$15.00 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$8.1m more in shares than they have sold in the last 12 months. Duyuru • Jul 23
Carlsmed, Inc. has completed an IPO in the amount of $100.5 million. Carlsmed, Inc. has completed an IPO in the amount of $100.5 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 6,700,000
Price\Range: $15
Discount Per Security: $1.05
Transaction Features: Sponsor Backed Offering 
